Flooding poses significant risks to communities in wetlands and densely urbanized regions, necessitating robust prevention ...

SOUTH SAN FRANCISCO - BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced Wednesday preliminary safety and efficacy data from three clinical-stage programs targeting RAS-pathway malignancies. The ...

BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients ...

BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed ...

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

本研究针对迪拜超干旱环境下极端降雨引发的城市内涝问题，开发了融合二维水动力模型与地理空间多准则决策分析的创新框架。研究人员通过耦合HEC-RAS雨打在网格模拟与GIS-MCDA-AHP方法，构建了水文灾害指数(HHI)，精准识别出43%城区属高风险区域，局部水深达2.5 ...